TrimTabs Asset Management LLC grew its position in shares of Abbott Laboratories (NYSE:ABT) by 5.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,979 shares of the healthcare product maker’s stock after purchasing an additional 1,001 shares during the period. Abbott Laboratories makes up approximately 1.3% of TrimTabs Asset Management LLC’s investment portfolio, making the stock its 10th biggest position. TrimTabs Asset Management LLC’s holdings in Abbott Laboratories were worth $1,677,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of the company. Oregon Public Employees Retirement Fund lifted its stake in Abbott Laboratories by 7,559.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 30,095,862 shares of the healthcare product maker’s stock worth $416,000 after purchasing an additional 29,702,943 shares during the last quarter. Norges Bank bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $1,239,454,000. FMR LLC raised its stake in shares of Abbott Laboratories by 118.2% during the fourth quarter. FMR LLC now owns 23,762,285 shares of the healthcare product maker’s stock valued at $1,718,726,000 after acquiring an additional 12,871,418 shares in the last quarter. BlackRock Inc. raised its stake in shares of Abbott Laboratories by 3.3% during the fourth quarter. BlackRock Inc. now owns 121,045,590 shares of the healthcare product maker’s stock valued at $8,755,228,000 after acquiring an additional 3,842,101 shares in the last quarter. Finally, Sustainable Growth Advisers LP raised its stake in shares of Abbott Laboratories by 147.4% during the fourth quarter. Sustainable Growth Advisers LP now owns 4,390,018 shares of the healthcare product maker’s stock valued at $317,530,000 after acquiring an additional 2,615,446 shares in the last quarter. Hedge funds and other institutional investors own 73.45% of the company’s stock.
In related news, SVP Jaime Contreras sold 918 shares of the company’s stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $73.12, for a total transaction of $67,124.16. Following the completion of the sale, the senior vice president now owns 34,706 shares of the company’s stock, valued at approximately $2,537,702.72. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brian B. Yoor sold 2,246 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $78.00, for a total transaction of $175,188.00. Following the completion of the sale, the chief financial officer now directly owns 116,627 shares of the company’s stock, valued at approximately $9,096,906. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,001,705 shares of company stock valued at $76,460,183. 0.70% of the stock is owned by corporate insiders.
Shares of Abbott Laboratories stock traded down $0.04 during trading hours on Wednesday, reaching $75.67. The stock had a trading volume of 3,350,302 shares, compared to its average volume of 4,604,591. The company has a market cap of $135.81 billion, a P/E ratio of 26.27, a price-to-earnings-growth ratio of 2.17 and a beta of 1.11. Abbott Laboratories has a twelve month low of $60.31 and a twelve month high of $80.74. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.13 and a current ratio of 1.58.
Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.02. Abbott Laboratories had a net margin of 8.53% and a return on equity of 16.86%. The business had revenue of $7.54 billion during the quarter, compared to the consensus estimate of $7.49 billion. During the same quarter in the prior year, the firm posted $0.59 earnings per share. The company’s revenue was up 2.0% compared to the same quarter last year. Equities research analysts forecast that Abbott Laboratories will post 3.22 EPS for the current year.
Several brokerages recently issued reports on ABT. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $88.00 price objective on the stock in a report on Tuesday, March 19th. Wells Fargo & Co reissued a “buy” rating on shares of Abbott Laboratories in a report on Thursday, March 14th. Royal Bank of Canada lifted their price objective on shares of Abbott Laboratories to $82.00 and gave the company a “buy” rating in a report on Monday, April 15th. They noted that the move was a valuation call. Barclays set a $84.00 price target on shares of Abbott Laboratories and gave the stock a “buy” rating in a report on Friday, March 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Abbott Laboratories in a report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $80.30.
TRADEMARK VIOLATION NOTICE: “TrimTabs Asset Management LLC Increases Holdings in Abbott Laboratories (ABT)” was originally posted by Sundance Herald and is owned by of Sundance Herald. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://sundanceherald.com/2019/05/29/abbott-laboratories-abt-shares-bought-by-trimtabs-asset-management-llc.html.
Abbott Laboratories Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Featured Story: Moving Average (MA)
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.